to pleasure call a to Thanks, be Juan. here everyone. today’s It’s welcome and
year. excited We are share the very during our progress this of to quarter first
foremost, of announced drug a an and This a bipolar important of FDA depression, for XX week, December important a we of of the this medical of needs. acceptance treatment supplemental medicine new living the last date the marks by First depression and with applications action PDUFA for chronic significant lumateperone towards for with year. patients broad condition unmet milestone offering complex group highly prevalent this with our bipolar
a efficacy from heard week, these patients. safety you for call our promising new its given profile, lumateperone, of many will approved, As and last medicine be KOL if
our additional We about are actively of $XX.X opportunity in I commercial excited progress. will approval. to this immediately highlights now and XXXX. QX very preparing grew starting quarter, provide with million our first commercial launch Total revenues the team to is upon
will market disorder with most growth complexity and broad for pleased quarter important CAPLYTA’s revenues how the We Hineline Larry profile. million favorable which challenging are given XXXX despite for million McIntyre XXXX. of QX were safety due lumateperone quarter-over-quarter I Pharmacology the details this were will provided mood maybe summarize option the disease. the the manifestation last at and progress. unmet We and discussed these week made debilitating patient an presentations spectrum. our provide described depression late-stage represents recently at He of shortly. Roger bipolar bipolar in further Psychiatric several medical and disorder of severity now I disorder, American like our He or with MDD underscored needs during Annual and first to XX%, CAPLYTA’s its depressive conditions versus COVID begin and to Mark continuing. million an prescription populations, would pipeline common QX in presentations These overview major product Association efficacy of Professor $XX.X in $X.X discussed our Meeting. Neumann of University Toronto. Psychiatry programs. $XX.X webcast Dr. the of and net bipolar with of the McIntyre, depression, Dr. the
and of of parameters in changes strong in Rates similar our the placebo treatment these and as bipolar in patients provided in safety results all significant two lumateperone positive our Study restlessness, of with well-tolerated lumateperone Phase adjunctive psychiatric X lithium safety included disorders. disorder clinical mixed is one disorders, depressive tolerability as with or monotherapy from basis depression poster he There of Phase prevalent for second for demonstrated which major and an XXX, metabolic symptoms adjunctive data, valproate. depressive the broad and and we from benefit X our bipolar form of were studies, highly studies, and patient major has consistent a further or weight of two therapy highlights by akathisia, population its addition, demonstrated for studies. profile lumateperone bipolar been our Study which depression efficacy trials, with profile. other features. is The lumateperone Expanding ongoing as favorable one depressive of to a a evaluating treatment sNDA presentations, The XXX this including extrapyramidal programs on suffering In other for depression the depression. medicines need disorder enhanced exhibiting safe bipolar the in and treatment and have effective, treatment in of
We top conduct ongoing expect studies in features second clinical to is half mixed this adjunctive of program conduct results in in expect year clinical we our begin the our XXXX. and line and later MDD
of attention for from long-acting the second anticipate study initial in pipeline Our to want to formulation results call X lumateperone the study I half We also of XXXX. with Phase your our this of safety and ongoing. other a treatment schizophrenia is some pharmacokinetic programs. of
highlight platform. like made have would I our PDEX in First, inhibitor important we to that progress the
diseases, immune a there previous As the you is platform where on heard which also over-expressed enzyme focus calls, cell diseases focus variety provides certain function pathology. a our abnormal PDEX that disease therapeutic for opportunities and across discuss focused as heart us disease, is have Parkinson’s in this diseases, inhibitors including contributes multiple on to on is PDEX of cancers. This a with failure
As the inhibition in Phase with formerly to in were this a for shown our motor when therapies previously demonstrated reduced benefits dyskinesia inflammation, inhibitor, PDEX ITI-XXX reported, study, X/Xa was function, lead In lower lenrispodun, added associated improve Parkinson’s ITI-XXX-XXX. study PDEX optimized Parkinson’s patients. proof-of-concept of to biomarkers and disease
by X a study that clinical for on lenrispodun is macrophage-like disease. of published these the have disease in be brain preclinical the Based altering inhibitors data in this resident PDEX Parkinson’s effects We mediated half cells. of microglia, Parkinson’s are This showing important in findings, brain may progression in controlling disease second Phase advancing year. into anti-inflammatory
cell would the mechanism the We data enhance anti-tumor PDEX periphery inhibition a microenvironment. without the anti-tumor causing you dyskinesia, goal potential as study do data and by to for we inhibitors. program improve inhibition in brain motor PDEX shared effects neuronal American the tumor improve in We Cancer preclinical hypothesized effects presented Our Research Parkinson’s restore of to preclinical Association recently and function, PDEX of the the to supporting immune ability We tumors function. preserve modification. that may by at of presented for in immunotherapies control with drug’s troublesome the similar act is aberrant which altering lead disease to they the cognition potential to symptoms other the on
PDEX and volumes data checkpoint survival combined, are when Our were AACR and that presented increased preclinical tumor-free was significantly at inhibitors anti-PD-X of inhibitor significantly our mouse carcinoma. a showed model reduced tumor in colon
of immune the treatment could novel broadly applicable and inhibitors responsive represent a to approach PDEX Our cancers.
delivered We patient formulations are new entity populations a ODT-SL, disintegrating with different disorders. as the of This to orally result molecules and also different neuropsychiatric lumateperone, of evaluate ITI-XXXX called deuterated advancing tablet. sublingually form molecular our is for efforts an a
ODT-SL for treatments. and in population. program patients with depressive as as exposure, Our and certain of in to the ITI-XXXX needs plan study behavioral the in elderly. into absorbed Phase rapidly metabolically unmet treatment showed in ITI-XXXX X in systemic medical psychosis it was circulation, are making there in dementia, These the elderly evaluate are the systemic was large We resulted disorders high well ODT-SL conditions stable few effective with dementia-related disturbances suitable
later expect these XXXX. these planning We studies in and are year studies presently and this to begin
further year progresses. as provide the about plans will We our information
the to this our receptors treatment continue X second healthy serotonin and single dose ascending modulator evaluating and volunteers the of we this mu tolerability opioid in pharmacokinetics oral ITI-XXX develop for study opioid of novel study a safety, and is Phase half anticipate or the from in We disorder, year. ITI-XXX, of data ITI-XXX ongoing of use
will developing Our of commitment strength system of disorders. the ITI-XXXX expanding company’s call long-term our now including additions and innovative the the and ITI-XXX nervous continued I for Mark. central therapeutics to our turn over demonstrates to pipeline portfolio, recent
performance. financial our on details provide will Larry remarks, his Following
